This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

VIVUS Announces Richard Fante, Former President U.S. And CEO North America, AstraZeneca, To Serve As Senior Advisor

Stocks in this article: VVUS

MOUNTAIN VIEW, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the Company) today announced that Richard Fante, former president U.S., CEO North America and regional vice president Americas at AstraZeneca, has agreed to provide advisory services to the Company. In this role, Mr. Fante will advise the Company regarding commercial options to access the primary care market and maximize the value of Qsymia ® (phentermine and topiramate extended-release) capsules CIV.

Mr. Fante has more than 20 years of experience in the pharmaceuticals sector. He has an established track record of constructing and managing strong teams and aligning large and small organizations to deliver results. His scope of responsibilities has ranged from building iconic pharmaceutical brands to leading an organization in excess of 7,000 employees and revenues of more than $12 billion. Among his main accomplishments at AstraZeneca were establishing Nexium ®, Crestor ® and Seroquel ® as three of the top 10 brands in the U.S. through well-articulated brand strategies and focused marketing and sales execution.

"We are excited to have an executive of Richard Fante's caliber advising VIVUS at this critical time," commented Leland Wilson, chief executive officer of VIVUS. "With the recent FDA approval of the REMS modification for Qsymia, and more payors recognizing medical obesity treatment, VIVUS is making significant progress on its commercialization strategies. Rich's vast experience and unique perspectives building several primary care products into market-leading brands will be extremely valuable as we seek to expand Qsymia's primary care presence."

Mr. Fante began his pharmaceutical career as a sales representative. In 1995, Mr. Fante joined AstraZeneca, where he rose through the commercial ranks and was promoted to various senior management roles within the organization, culminating in his appointment as president of the U.S. business in 2008 and CEO for North America in 2009. In 2011, he assumed responsibility for Central and South America. He holds a bachelor's degree in biology from Princeton University and a master's in business administration from the University of North Carolina.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs